SCHEMBL19720585

SCHEMBL19720585

O=C(O)CCCN1CC(F)(F)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.53
MAPK1 P28482 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
LMNA P02545 3/20 0.40
SLC22A6 Q4U2R8 1/20 0.40
TSHR P16473 2/20 0.39
NFKB1 P19838 1/20 0.39
PMP22 Q01453 1/20 0.39
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
CAMK2A Q9UQM7 1/20 0.36
APEX1 P27695 1/20 0.35
GABRR3 A8MPY1 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
HDAC3 O15379 1/20 0.34
GABBR2 O75899 1/20 0.34
THRB P10828 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30854371 0.82 CYP1A2 (0.58) CYP1A2MAPK1SMN1; SMN2SLC6A1GLA
SCHEMBL30854439 0.80 CYP1A2 (0.60) CYP1A2MAPK1SMN1; SMN2LMNASLC22A6
SCHEMBL18939342 0.77 CYP1A2 (0.51) CYP1A2MAPK1SMN1; SMN2LMNATSHR
SCHEMBL8947664 0.75
SCHEMBL8377176 0.75 CYP1A2 (0.78) CYP1A2MAPK1SMN1; SMN2LMNASLC22A6
SCHEMBL3409970 0.74 GLA (0.45) CYP1A2MAPK1SMN1; SMN2LMNASLC22A6
SCHEMBL14671225 0.73 HSD17B10 (0.41) TSHR
SCHEMBL857572 0.71 SMN1; SMN2 (0.95) CYP1A2MAPK1SMN1; SMN2LMNASLC22A6
SCHEMBL472290 0.70 SMN1; SMN2 (1.00) CYP1A2MAPK1SMN1; SMN2LMNASLC22A6
Hydrochloric Acid SCHEMBL946654 0.70 SMN1; SMN2 (0.91) CYP1A2MAPK1SMN1; SMN2LMNASLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3257848-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY Novartis AG (CH) 2017-12-20 EP disclosed